Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-870-1000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$22.25 million
Profitability
Miscellaneous
Employees79
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Calithera Biosciences (NASDAQ:CALA) Frequently Asked Questions
What is Calithera Biosciences' stock symbol?
Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."
How were Calithera Biosciences' earnings last quarter?
Calithera Biosciences Inc (NASDAQ:CALA) released its quarterly earnings data on Thursday, August, 8th. The biotechnology company reported ($0.58) EPS for the quarter, missing analysts' consensus estimates of ($0.55) by $0.03. View Calithera Biosciences' Earnings History.
When is Calithera Biosciences' next earnings date?
What price target have analysts set for CALA?
2 brokers have issued 1 year target prices for Calithera Biosciences' shares. Their forecasts range from $8.00 to $8.00. On average, they anticipate Calithera Biosciences' stock price to reach $8.00 in the next year. This suggests a possible upside of 106.2% from the stock's current price. View Analyst Price Targets for Calithera Biosciences.
What is the consensus analysts' recommendation for Calithera Biosciences?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Calithera Biosciences.
Has Calithera Biosciences been receiving favorable news coverage?
Headlines about CALA stock have trended somewhat negative this week, according to InfoTrie. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Calithera Biosciences earned a coverage optimism score of -1.3 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Calithera Biosciences.
Are investors shorting Calithera Biosciences?
Calithera Biosciences saw a increase in short interest in August. As of August 31st, there was short interest totalling 1,176,200 shares, an increase of 8.5% from the July 31st total of 1,083,600 shares. Based on an average trading volume of 435,300 shares, the days-to-cover ratio is currently 2.7 days. Currently, 3.4% of the company's stock are short sold. View Calithera Biosciences' Current Options Chain.
Who are some of Calithera Biosciences' key competitors?
Some companies that are related to Calithera Biosciences include Rhythm Pharmaceuticals (RYTM), Principia Biopharma (PRNB), Emisphere Technologies (EMIS), Eagle Pharmaceuticals (EGRX), Cytokinetics (CYTK), CannTrust (CNTTF), ZEALAND PHARMA/S (ZEAL), Endo International (ENDP), Kura Oncology (KURA), Urogen Pharma (URGN), ZIOPHARM Oncology (ZIOP), Stoke Therapeutics (STOK), Vanda Pharmaceuticals (VNDA), Capstone Therapeutics (CAPS) and Karyopharm Therapeutics (KPTI).
What other stocks do shareholders of Calithera Biosciences own?
Who are Calithera Biosciences' key executives?
Calithera Biosciences' management team includes the folowing people:
- Dr. Susan M. Molineaux, Co-Founder, CEO, Pres & Director (Age 65)
- Ms. Sumita Ray, Sr. VP, Gen. Counsel & Chief Compliance Officer (Age 45)
- Dr. Keith Orford, Chief Medical Officer (Age 47)
- Ms. Stephanie Wong, Sr. VP of Fin. & Sec. (Age 45)
- Ms. Jennifer McNealey, VP of Investor Relations & Strategy
Who are Calithera Biosciences' major shareholders?
Calithera Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.23%), Vanguard Group Inc. (5.39%), Point72 Asset Management L.P. (4.93%), CVI Holdings LLC (1.57%), Renaissance Technologies LLC (1.91%) and Sofinnova Investments Inc. (1.35%). Company insiders that own Calithera Biosciences stock include Adage Capital Partners Gp, LL, Keith Orford and Susan Molineaux. View Institutional Ownership Trends for Calithera Biosciences.
Which institutional investors are selling Calithera Biosciences stock?
Which institutional investors are buying Calithera Biosciences stock?
CALA stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., CVI Holdings LLC, Sofinnova Investments Inc., Vanguard Group Inc., Monashee Investment Management LLC, Renaissance Technologies LLC, Citadel Advisors LLC and BlackRock Inc.. View Insider Buying and Selling for Calithera Biosciences.
How do I buy shares of Calithera Biosciences?
Shares of CALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Calithera Biosciences' stock price today?
One share of CALA stock can currently be purchased for approximately $3.88.
How big of a company is Calithera Biosciences?
Calithera Biosciences has a market capitalization of $208.63 million and generates $22.25 million in revenue each year. The biotechnology company earns $-54,630,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis. Calithera Biosciences employs 79 workers across the globe.View Additional Information About Calithera Biosciences.
What is Calithera Biosciences' official website?
How can I contact Calithera Biosciences?
Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-870-1000 or via email at [email protected]
MarketBeat Community Rating for Calithera Biosciences (NASDAQ CALA)
MarketBeat's community ratings are surveys of what our community members think about Calithera Biosciences and other stocks. Vote "Outperform" if you believe CALA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CALA will underperform the S&P 500 over the long term. You may vote once every thirty days.
